SAGE Therapeutics (SAGE) Misses Q1 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Goldman Sachs Starts Sage Therapeutics (SAGE) at Buy
May 15, 2015 7:02 AM EDTGoldman Sachs initiated coverage on Sage Therapeutics (NASDAQ: SAGE) with a Buy rating and a price target of $80.00.
For an analyst ratings summary and ratings history on Sage Therapeutics click here. For more ratings news on Sage Therapeutics click here.
Shares of Sage Therapeutics closed at $58.29 yesterday.
... MoreSage Therapeutics (SAGE) PT Raised to $70 at Leerink Partners as New Data Corroborates Prior Promising Results
May 14, 2015 11:03 AM EDTLeerink Partners analyst Paul Matteis reiterated an Outperform rating and boosted his price target on Sage Therapeutics (NASDAQ: SAGE) to $70.00 (from $54.00) after final phase I/II SAGE-457 data corroborates prior promising results.
Matteis commented, "This morning SAGE reported final... More
SAGE Therapeutics (SAGE) Issues Positive Update on SAGE-547; Primary Endpoint Met
May 14, 2015 6:18 AM EDTSAGE Therapeutics (NASDAQ: SAGE) announced that SAGE-547 demonstrated robust activity, with a 77 percent response rate in evaluable patients with super-refractory status epilepticus (SRSE), in a successfully completed Phase 1/2 clinical trial. SAGE-547 also demonstrated favorable tolerability and a benefit-risk profile supporting development in this acutely ill patient population. SRSE is a critical condition in which the brain is in a state of persistent seizure, where patients are placed in a medically induced coma in an attempt to stabilize them and where conventional and approved therapies fail to awaken the patients. Currently, there are no therapies... More
